Thursday, October 22, 2020
Home Latest Pharma-News COVID-19 vaccine AZD1222 clinical trial resumed in Japan

COVID-19 vaccine AZD1222 clinical trial resumed in Japan

 October 2020: “The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

A standard review process triggered a voluntary pause to vaccination across all global trials on 6 September to allow review of safety data by an independent committee.

- Advertisement -

Their recommendations have been supported by international regulators in the UK, Brazil, South Africa, India and now in Japan, who have deemed that the trials are safe to resume.

AstraZeneca continues to work with the FDA to facilitate review of the information needed to make a decision regarding resumption of the US trial.

The safety of trial participants is of paramount importance and we are committed to upholding the highest standards of conduct in clinical trials.

AZD1222

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech.

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.”


https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

two + five =

Most Popular

AZ’s Tagrisso scores priority review from FDA with EGFR-mutated lung cancer

October 20, 2020: "AstraZeneca’s Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in...

Forxiga recommended for approval in the EU by CHMP for heart failure

October 19, 2020: "AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the...

AstraZeneca advances leadership in renal disease at ASN Kidney Week 2020 Reimagined

October 20, 2020: AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which...

AbbVie’s VENCLEXTA® Receives FDA Approval for Acute Myeloid Leukemia

October 16, 2020: "AbbVie announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination...